Condition
Attention-Deficit Hyperactivity Disorder(ADHD)
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Centanafadine
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2/3 (1)
Phase 3 (1)
Trial Status
Recruiting2
Clinical Trials (2)
Research Network
Common Treatments
- Centanafadine2
Active Sponsors
- Otsuka Pharmaceutical Co., Ltd.2
Top Investigators
Otsuka Pharmaceutical Co., Ltd.